Fundraising Fox
Myriad Genetics
Salt Lake City, US · 3 known investors
Find your way into Myriad Genetics
Sign up to see every warm intro you have to Myriad Genetics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Myriad Genetics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Myriad Genetics is a genetic testing and precision medicine company that delivers molecular diagnostic test results across hereditary cancer risk, reproductive health, oncology, urology, and mental health. It serves patients and healthcare providers with insights to help detect, treat, and prevent disease.
Founders & leadership
Investors · 3
How we know: OrbiMed's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$249.4K disclosed across 1 round · 2019
▶$249.4KraisedFeb 2019 · 1 investors · BiotechnologyRule 506(b)
- Richard MarshExecutive Officer
- Lawrence C. BestDirector
- W. Lloyd SandersExecutive Officer
- Dennis LangerDirector
- Mark C. CaponeExecutive Officer, Director
- S. Louise PhanstielDirector
- Alexander FordExecutive Officer
- Bernard F. TobinExecutive Officer
- Helner DreismannDirector
- Walter GilbertDirector
- Mark VerrattiExecutive Officer
- Gary A. KingExecutive Officer
- John T. HendersonDirector
- Richard Bryan RiggsbeeExecutive Officer
- Ralph L. McDadeExecutive Officer
- Jerry S. LanchburyExecutive Officer
- Offering amount
- $249.4K
- Amount sold
- $249.4K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 2
Early investors' stakes continue via these dealsCounsyl was a clinical genetic-screening company offering DNA carrier screening for family planning, prenatal screening, and inherited cancer risk tests, processed in its own CLIA-certified lab. Co-founded in 2007 with Balaji Srinivasan as CTO, it screened hundreds of thousands of patients before Myriad Genetics acquired it for $375 million in 2018.
Molecular diagnostics; acquired by Myriad Genetics
Frequently asked questions
- What does Myriad Genetics do?
- Myriad Genetics is a genetic testing and precision medicine company that delivers molecular diagnostic test results across hereditary cancer risk, reproductive health, oncology, urology, and mental health. It serves patients and healthcare providers with insights to help detect, treat, and prevent disease.
- Who are Myriad Genetics's investors?
- Myriad Genetics's investors include OrbiMed, Hack VC, Ten VC.
- How much funding has Myriad Genetics raised?
- Myriad Genetics has disclosed $249.4K raised across 1 round.
- Where is Myriad Genetics headquartered?
- Myriad Genetics is headquartered in Salt Lake City, US.